JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 23, 2008; DOI: 10.1124/jpet.107.135186


0022-3565/08/3263-949-956$20.00
JPET 326:949-956, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.135186v1
326/3/949    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Roque, T.
Right arrow Articles by Jacquot, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roque, T.
Right arrow Articles by Jacquot, J.

CELLULAR AND MOLECULAR

Proinflammatory Effect of Sodium 4-Phenylbutyrate in {Delta}F508-Cystic Fibrosis Transmembrane Conductance Regulator Lung Epithelial Cells: Involvement of Extracellular Signal-Regulated Protein Kinase 1/2 and c-Jun-NH2-Terminal Kinase Signaling

Telma Roque, Emilie Boncoeur, Vinciane Saint-Criq, Elise Bonvin, Annick Clement, Olivier Tabary, and Jacky Jacquot

Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche-S 893, Paris, France (T.R., E.B., V.S.-C., E.B., A.C., O.T., J.J.); Université Pierre et Marie Curie, Université Paris 06, Paris, France (T.R., E.B., V.S.-C., E.B., A.C., O.T., J.J.); and Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Pediatric Pulmonary Department, Paris, France (A.C.)

Sodium 4-phenylbutyrate (4-PBA) has attracted a great deal of attention in cystic fibrosis (CF) pathology due to its capacity to traffic {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) to the cell membrane and restore CFTR chloride function at the plasma membrane of CF lung cells in vitro and in vivo. Using two different {Delta}F508-CFTR lung epithelial cell lines (CFBE41o- and IB3-1 cells, characterized with {Delta}F508-homozygous and heterozygous genotype, respectively) in vitro, 4-PBA induced an increase of proinflammatory cytokine interleukin (IL)-8 production in a concentration-dependent manner. This 4-PBA-induced IL-8 production was associated with a strong reduction of proteasome and nuclear factor-{kappa}B transcriptional activities in the two {Delta}F508-CFTR lung cells either in a resting state or after tumor necrosis factor-{alpha} stimulation. In contrast, a strong increase of activator protein-1 transcriptional activity was observed. The inhibition of extracellular signal-regulated protein kinase 1/2 (ERK1/2) by 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene (U0126) and 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059) and c-Jun-NH2-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) by anthra[1,9-cd] pyrazol-6 (2H)-one (SP600125), respectively, was associated with a reduction (2–3.5-fold) of IL-8 production in both {Delta}F508-CFTR lung cell lines treated with 4-PBA. No significant change of IL-8 production was observed after an inhibition of p38 MAPK with 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl] phenol (SB202190). Therefore, we suggest that inhibition of both ERK1/2 and JNK signaling may be a means to strongly reduce 4-PBA-induced IL-8 production in combination with 4-PBA treatment to restore CFTR Cl- channel function in lung epithelial cells of patients with CF.


Received December 19, 2007; accepted June 20, 2008.

Address correspondence to: Dr. Jacky Jacquot, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche-S 893, Hôpital Saint-Antoine, 184, rue du Fg Saint-Antoine, 75012 Paris, France. E-mail: jacky.jacquot{at}inserm.fr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.